Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H4 monoclonal antibody NC762

A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-B7-H4 monoclonal antibody NC762 binds to B7-H4 on the surface of tumor cells. This may induce antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells, which leads to the inhibition of tumor cell proliferation. In addition, the Fc region of NC762 contains three point mutations. This enhances its binding affinity for human FcgammaRIIIa receptors (CD16a) on natural killer (NK) cells, resulting in enhanced ADCC against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses. However, the anti-tumor activity of NC762 is not dependent upon T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:NC 762
NC-762
NC762
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search